LINCOLN636.70

Lincoln Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSIGACHITHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYAHCLMcap ₹1,275 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+7.7+7.5
EBITDA-3.8-1.1
Net Income+6.7-2.9
Total Assets+11.7+12.8
Total Equity+12.8+13.0
Free Cash Flow+8.6+83.9
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.